Laurion Capital Management LP Chinook Therapeutics, Inc. Transaction History

Laurion Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $100,204 - $207,174	-5,370 Reduced 0.65%	824,380 $31.7 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $11,979 - $17,586	643 Added 0.08%	829,750 $21.7 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $11,258 - $15,026	-643 Reduced 0.08%	829,107 $16.3 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $944,250 - $1.41 Million	75,000 Added 9.94%	829,750 $14.5 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $2.41 Million - $3.35 Million	200,500 Added 36.18%	754,750 $12.3 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $5.92 Million - $9.33 Million	554,250 New	554,250 $9.04 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.